Key Points
- CEO Amir Heshmatpour bought 30,000 shares at an average price of $5.02, spending $150,600 and increasing his direct holdings to 3.353 million shares.
- Neonc reported a quarterly loss of $0.28 per share, missing the consensus estimate of a $0.25 loss by $0.03.
- Analyst coverage is mixed but averages to a “Moderate Buy” rating, with a consensus price target of $16; shares traded at $4.91 on Friday.
Neonc Technologies Holdings, Inc. (NASDAQ:NTHI - Get Free Report) CEO Amir Heshmatpour purchased 30,000 shares of the firm's stock in a transaction that occurred on Friday, November 13th. The stock was bought at an average price of $5.02 per share, for a total transaction of $150,600.00. Following the transaction, the chief executive officer directly owned 3,353,000 shares of the company's stock, valued at $16,832,060. This trade represents a 0.90% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.
Neonc Technologies Price Performance
Shares of NASDAQ:NTHI traded up $0.06 during midday trading on Friday, hitting $4.91. The stock had a trading volume of 251,853 shares, compared to its average volume of 118,828. The company's 50-day moving average price is $3.30 and its 200-day moving average price is $5.27. Neonc Technologies Holdings, Inc. has a fifty-two week low of $2.50 and a fifty-two week high of $11.38.
Neonc Technologies (NASDAQ:NTHI - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.03).
Hedge Funds Weigh In On Neonc Technologies
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE bought a new position in shares of Neonc Technologies during the 2nd quarter valued at approximately $1,017,000. BlackRock Inc. bought a new stake in shares of Neonc Technologies in the 2nd quarter worth approximately $815,000. Westmount Partners LLC lifted its stake in Neonc Technologies by 355.2% in the second quarter. Westmount Partners LLC now owns 197,178 shares of the company's stock valued at $893,000 after purchasing an additional 153,858 shares during the last quarter. Marshall Wace LLP lifted its stake in Neonc Technologies by 423.5% in the third quarter. Marshall Wace LLP now owns 114,046 shares of the company's stock valued at $388,000 after purchasing an additional 92,262 shares during the last quarter. Finally, Global Retirement Partners LLC bought a new position in Neonc Technologies during the second quarter valued at $126,000.
Wall Street Analysts Forecast Growth
NTHI has been the subject of a number of research reports. Wall Street Zen upgraded Neonc Technologies from a "sell" rating to a "hold" rating in a research note on Saturday, November 7th. Roth Capital initiated coverage on shares of Neonc Technologies in a report on Thursday, September 24th. They issued a "buy" rating on the stock. Zacks Research upgraded shares of Neonc Technologies from a "strong sell" rating to a "hold" rating in a research note on Thursday, November 5th. Weiss Ratings cut shares of Neonc Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, October 21st. Finally, BTIG Research restated a "buy" rating and set a $15.00 price target on shares of Neonc Technologies in a report on Tuesday, September 8th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Neonc Technologies currently has an average rating of "Moderate Buy" and an average target price of $16.00.
View Our Latest Stock Analysis on NTHI
About Neonc Technologies
(
Get Free Report)
NeOnc Technologies Holdings, Inc. is a biotechnology company developing treatments for brain tumors and other central nervous system cancers. Its research focuses on approaches intended to deliver therapies to the brain, where the blood-brain barrier can limit the effectiveness of conventional treatments. The company's pipeline includes NEO100, a formulation of perillyl alcohol designed for intranasal delivery, and NEO212, a compound combining perillyl alcohol with temozolomide. These candidates are being developed for potential use in brain cancer treatment.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
